دورية أكاديمية
A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022.
| العنوان: | A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022. |
|---|---|
| المؤلفون: | Qureshi H; National Focal Point Hepatitis for Pakistan, Islamabad, Pakistan., Mahmood H; Hepatitis Planning, Development and Monitoring Unit (PDMU), Islamabad, Pakistan., Nasir Z; Citilab, Islamabad, Pakistan., Siddique S; Core Diagnostics, Abbott Pakistan, Karachi, Pakistan., Averhoff F; Infectious Disease Research Abbott and the Abbott Pandemic Defense Coalition (APDC), Abbott Park, IL, USA., Cloherty G; Infectious Disease Research Abbott and the Abbott Pandemic Defense Coalition (APDC), Abbott Park, IL, USA. |
| المصدر: | Journal of viral hepatitis [J Viral Hepat] 2024 Aug; Vol. 31 (8), pp. 500-503. Date of Electronic Publication: 2024 May 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford ; Boston : Blackwell Scientific Publications, 1994- |
| مواضيع طبية MeSH: | Antiviral Agents*/therapeutic use , Hepatitis C*/diagnosis , Hepatitis C*/drug therapy , Hepacivirus*/genetics , Hepacivirus*/immunology , Police*, Humans ; Pakistan/epidemiology ; Male ; Female ; Adult ; Middle Aged ; Young Adult ; Viral Core Proteins/blood ; Hepatitis C Antigens/blood ; Aged ; Adolescent ; Pilot Projects ; Mass Screening/methods ; Hepatitis C Antibodies/blood ; Carbamates ; Imidazoles ; Pyrrolidines ; Valine/analogs & derivatives |
| مستخلص: | Hepatitis C virus core antigen (HCVcAg) testing can simplify and decrease costs of HCV infection confirmation compared to molecular testing (nucleic acid testing). We piloted HCVcAg testing for the confirmation of active infection. The study was conducted during June through December 2022 among the police and the general population of Islamabad, Pakistan age 18 years and older. Initial screening for HCV antibody was conducted using a rapid diagnostic test (RDT) for all consenting participants. Those who tested positive had venous blood samples tested for HCVcAg, platelets and aspartate aminotransferase (AST). Persons with HCVcAg values ≥3 fmol/L were defined as viremic, and they were offered treatment with direct acting antiviral (DAA) medications, sofosbuvir and daclatasvir. Aspartate aminotransferase to platelet ratio index (APRI) was calculated for each HCV infected person, and those with an APRI score <1.5 received treatment for 12 weeks, while those with APRI ≥ to 1.5 received 24 weeks of treatment. A total of 15,628 persons were screened for anti-HCV using RDT and 643 (4.1%) tested positive. HCVcAg values of ≥3 fmol/L was found in 399/643 (62.1%), and all were offered and accepted treatment. Of those treated, 273/399 (68.4%) returned for a follow-up SVR and HCVcAg was not detected in 261/273, a 95.6% cure rate. The pilot study demonstrated the effectiveness of reaching and treating an urban population using RDT for screening and HCVcAg for confirmation of infection and test of cure. (© 2024 The Author(s). Journal of Viral Hepatitis published by John Wiley & Sons Ltd.) |
| References: | Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl 1):s15‐s23. Gower E, Estes C, Blach S, Razavi‐Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):s45‐s57. doi:10.1016/j.jhep.2014.07.027. Qureshi H. Sindh serosurvey report 2020 WHO regional office Pakistan. Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point‐of‐care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn. 2017;17(12):1109‐1115. doi:10.1080/14737159.2017.1400385. Applegate TL, Fajardo E, Sacks JA. Hepatitis C virus diagnosis and the holy grail. Infect Dis Clin N Am. 2018;32(2):425‐445. doi:10.1016/j.idc.2018.02.010. Catlett B, Lamoury FMJ, Bajis S, et al. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study. J Viral Hepat. 2019;26(12):1423‐1430. doi:10.1111/jvh.13196. World Health Organization (WHO). Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection. World Health Organization; 2022 https://www.who.int/publications/i/item/9789240052710. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170‐1218. doi:10.1016/j.jhep.2020.08.018. Cloherty G, Talal A, Coller K, et al. Role of serologic and molecular diagnostic assays in identification and Management of Hepatitis C Virus Infection. J Clin Microbiol. 2016;54(2):265‐273. doi:10.1128/JCM.02407-15. Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost‐effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62(5):1396‐1404. doi:10.1002/hep.27966. Qureshi H. Use of HCV antigen test to detect hepatitis C virus. Paper presented in Pak Soc Of Gastroenterology, 2011, PC hotel, Karachi. Abid A, Uddin M, Muhammad T, et al. Evaluation of hepatitis C virus core antigen assay in a resource‐limited setting in Pakistan. Diagnostics (Basel). 2021;11(8):1354. doi:10.3390/diagnostics11081354. Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta‐analysis. Ann Intern Med. 2016;165:345‐355. The Pakistan Health Research Council (PHRC), Ministry of National Health Services, Regulations and Coordination (NHSRC) and Provincial Health Departments. Guidelines for the Treatment of the Persons with Chronic Hepatitis C Infection. Pakistan Health Research Council (PHRC); 2020. Bureau of Statistics (BoS), Planning & Development, Department Government of Punjab. Population Based Prevalence Survey of Hepatitis B & C Punjab. Bureau of Statistics (BoS); 2018. HCV Health Policy Tool – Pakistan. Final Assumptions/Inputs and Scenarios. Centre for Data Analysis USA. 2021. Qureshi H, Mahmood H, Ahmed N, et al. A model screen test and treat hepatitis C elimination project among underserved communities in Islamabad‐the federal capital of Pakistan. J Hepatol. 2022;77:S215‐S216. |
| معلومات مُعتمدة: | Abbott Laboratories |
| فهرسة مساهمة: | Keywords: HCV; antiviral agents; daclatasvir; hepatitis C testing; molecular diagnostic techniques; pilot projects; police; rapid diagnostic tests; sofosbuvir; urban population |
| المشرفين على المادة: | 0 (Antiviral Agents) 0 (Viral Core Proteins) 0 (Hepatitis C Antigens) 0 (Hepatitis C Antibodies) LI2427F9CI (daclatasvir) 0 (nucleocapsid protein, Hepatitis C virus) 0 (Carbamates) 0 (Imidazoles) 0 (Pyrrolidines) HG18B9YRS7 (Valine) |
| تواريخ الأحداث: | Date Created: 20240521 Date Completed: 20240724 Latest Revision: 20240724 |
| رمز التحديث: | 20240725 |
| DOI: | 10.1111/jvh.13953 |
| PMID: | 38771312 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2893 |
|---|---|
| DOI: | 10.1111/jvh.13953 |